Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma.
暂无分享,去创建一个
R. Stupp | M. J. van den Bent | M. Weller | A. Brandes | T. Gorlia | W. Wick | A. Jacobs | M. Bent | E. Franceschi | M. Weller | B. Baumert | A. Jacobs | W. Wick